Prognosis and Guideline-Adherent Antithrombotic Treatment in Patients With Atrial Fibrillation and Atrial Flutter Implications of Undertreatment and Overtreatment in Real-life Clinical Practice; the Loire Valley Atrial Fibrillation Project

被引:70
作者
Gorin, Laurent [1 ,3 ]
Fauchier, Laurent [1 ,2 ]
Nonin, Emilie [1 ,3 ]
Charbonnier, Bernard [1 ,2 ]
Babuty, Dominique [1 ,2 ]
Lip, Gregory Y. H. [4 ]
机构
[1] CHU Trousseau, Serv Cardiol B, F-37044 Tours, France
[2] Univ Tours, Fac Med, Tours, France
[3] Hop Cardiovasc & Pneumol Louis Pradel, Bron, France
[4] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England
关键词
HEART RHYTHM ASSOCIATION; EUROPEAN-SOCIETY; TASK-FORCE; CARDIOLOGY COMMITTEE; AMERICAN-COLLEGE; HIGH-RISK; STROKE; MANAGEMENT; THERAPY; ANTICOAGULATION;
D O I
10.1378/chest.10-2436
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: In patients with atrial fibrillation (AF), adherence to guidelines for antithrombotic treatment is poorly followed, and undertreatment (or nonadherence with guidelines) is associated with a worse prognosis. The study objective was to evaluate whether this was also the case in a large contemporary series of unselected patients with AF in real-world clinical practice. Methods: All patients with AF or atrial flutter seen in our institution between 2000 and 2007 were identified in a database and followed up for mortality and stroke. Antithrombotic guideline adherence was assessed according to the 2006 American College of Cardiology/American Heart Association/European Society of Cardiology guidelines. Results: We reviewed outcomes in 3,646 consecutive patients with AF or atrial flutter (aged 71 +/- 14 years; mean CHAOS:, [congestive heart failure, hypertension, aged >= 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score, 1.5 +/- 1.1). Antithrombotic treatment was in agreement with the guidelines in 53% of patients, whereas 31% were classified as undertreated and 16% as overtreated. Among other parameters, nonpermanent AF and atrial flutter were independently associated with an increased risk of undertreatment. After a follow-up of 953 +/- 767 days (median, 771 days; interquartile range, 1,286 days), guideline adherence was associated with a lower risk of adverse events (death from all causes or stroke) compared with undertreatment (relative risk, 0.47; 95% CI, 0.40-0.55; P<.0001). Overtreatment was associated with a lower risk of adverse events compared with the guideline-adherent population (relative risk, 0.40; 95% CI, 0.28-0.58; P<.0001). Factors independently associated with increased risk of mortality or stroke were antithrombotic undertreatment, older age, heart failure, renal failure, diabetes, male sex, and previous history of stroke. Conclusions: Guideline nonadherence and undertreatment with antithrombotic agents in unselected real-world patients with AF or atrial flutter are independently associated with a high risk of stroke and mortality. CHEST 2011; 140(4):911-917
引用
收藏
页码:911 / 917
页数:7
相关论文
共 24 条
[1]  
[Anonymous], THROMB HAEMOST
[2]  
Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]
[3]   Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W [J].
De Caterina, Raffaele ;
Connolly, Stuart J. ;
Pogue, Janice ;
Chrolavicius, Susan ;
Budaj, Andrzej ;
Morais, Joao ;
Renda, Giulia ;
Yusuf, Salim .
EUROPEAN HEART JOURNAL, 2010, 31 (17) :2133-2140
[4]   ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation -: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology [J].
Fuster, V ;
Rydén, LE ;
Asinger, RW ;
Cannom, DS ;
Crijns, HJ ;
Frye, RL ;
Halperin, JL ;
Kay, GN ;
Klein, WW ;
Lévy, S ;
McNamara, RL ;
Prystowsky, EN ;
Wann, LS ;
Wyse, DG .
EUROPEAN HEART JOURNAL, 2001, 22 (20) :1852-1923
[5]   ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation -: executive summary -: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [J].
Fuster, Valentin ;
Ryden, Lars E. ;
Cannom, David S. ;
Crijns, Harry J. ;
Curtis, Anne B. ;
Ellenbogen, Kenneth A. ;
Halperin, Jonathan L. ;
Le Heuzey, Jean-Yves ;
Kay, G. Neal ;
Lowe, James E. ;
Olsson, S. Bertil ;
Prystowsky, Eric N. ;
Tamargo, Juan Luis ;
Wann, Samuel ;
Priori, Silvia G. ;
Blanc, Jean-Jacques ;
Budaj, Andrzej ;
Camm, John ;
Dean, Veronica ;
Deckers, Jaap W. ;
Despres, Catherine ;
Dickstein, Kenneth ;
Lekakis, John ;
McGregor, Keith ;
Metra, Marco ;
Morais, Joao ;
Osterspey, Ady ;
Tamargo, Juan Luis ;
Zamorano, Jose Luis ;
Smith, Sidney C. ;
Jacobs, Alice K. ;
Adams, Cynthia D. ;
Anderson, Jeffery L. ;
Antman, Elliott M. ;
Halperin, Jonathan L. ;
Hunt, Sharon Ann ;
Nishimura, Rick ;
Ornato, Joseph P. ;
Page, Richard L. ;
Riegel, Barbara .
EUROPEAN HEART JOURNAL, 2006, 27 (16) :1979-2030
[6]   Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].
Gage, BF ;
Waterman, AD ;
Shannon, W ;
Boechler, M ;
Rich, MW ;
Radford, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870
[7]   Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1 [J].
Gorin, Laurent ;
Fauchier, Laurent ;
Nonin, Emilie ;
de Labriolle, Axel ;
Haguenoer, Ken ;
Cosnay, Pierre ;
Babuty, Dominique ;
Charbonnier, Bernard .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) :833-840
[8]   Randomized Clinical Trials and Observational Studies Guidelines for Assessing Respective Strengths and Limitations [J].
Hannan, Edward L. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (03) :211-217
[9]   Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation - Analysis of 2012 participants in the SPAF I-III clinical trials [J].
Hart, RG ;
Pearce, LA ;
McBride, R ;
Rothbart, RM ;
Asinger, RW .
STROKE, 1999, 30 (06) :1223-1229
[10]   Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation [J].
Hart, Robert G. ;
Pearce, Lesly A. ;
Aguilar, Maria I. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (12) :857-867